Healthcare

Healthcare has always required a multi-disciplinary approach encompassing expertise in life sciences, pharmaceuticals, medical devices, materials, electronics, software and more.

With more than 200 attorneys covering every technology as well as lawyers dealing with life cycle commercial agreements, HGF is ideally placed to offer the best combination of industry-specific expertise for any client in the healthcare sector. HGF represents the full spectrum of healthcare clients from global pharmaceutical companies to SMEs and start-ups.

This cross-disciplinary approach is more important than ever with the adoption of AI and other digital technologies into all aspects of healthcare innovation. With developments in personalised medicine, use of AI, big data, robotics, VR, new drug delivery systems and CRISPR technology as well as global healthcare challenges requiring rapid and collaborative response, HGF’s large multidisciplinary teams are the ideal support in this rapidly evolving and complex sector.

Find a specialist
MRI scan
Lab technician

Our healthcare specialists

We’ve built our business by recruiting and developing specialists, not generalists. When it comes to protecting your ideas and business, you want to know you’re working with the best – people who truly understand your sector and the potential of your IP.

HGF’s team has healthcare professionals from an array of academic and business backgrounds. Our team-based approach ensures our clients benefit from the very best strategic advice from people who understand not only the legal environment but also the practical side of your business.

Let's talk

If you would like to discuss how HGF could help you, contact one of our healthcare specialists.

Contact us

Latest news

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details
See all updates